David Alan Campbell - Dec 3, 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Signature
/s/ James Pennington, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Dec 3, 2024
Transactions value $
-$1,005,000
Form type
4
Date filed
12/3/2024, 08:00 PM
Previous filing
Nov 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Sale -$1.01M -15K -5.84% $67.00 242K Dec 3, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.